Editorially reviewed by Dr Fatimah Khan, registered with the Pakistan Medical and Dental Council (PMDC no. 104595-P). Editorial medical reviewer; does not prescribe or review patient assessments.
Review details
Review recorded:
Review scope: This article edition.
Editorial reviewer for Prescrivia. Editorial review does not establish participation in patient consultations.
Clinical review does not replace individual medical advice. Prescrivia is a technology intermediary; independent doctors make clinical decisions.
Legal review: Qualified review pending.
Language review: Qualified review pending.
Source and review
Source published:
Attributed source update:
Text edited:
Editorial role: Editorial team. This description does not establish an individual credential or clinical review of this edition.
Read our editorial policy and corrections. Edit dates and source descriptions do not establish qualified review.
How does famotidine differ from a PPI?
Famotidine is an H2-receptor blocker. It reduces stomach-acid production by blocking histamine's action at H2 receptors. Proton-pump inhibitors (PPIs), such as omeprazole, reduce acid through a different mechanism.
The UK famotidine product information and NHS omeprazole guide describe different medicines, not a universal ranking of long-term safety.
Choosing a class depends on the problem
| Question | Why it matters |
|---|---|
| Are the symptoms occasional, persistent or associated with a diagnosed condition? | The appropriate investigation and treatment plan can differ |
| Is there an ulcer or oesophagitis? | Symptom relief alone does not establish healing or exclude another cause |
| Have symptoms changed or persisted despite treatment? | Repeatedly changing acid-suppressing medicines can delay review |
| Are other medicines affected by stomach acidity? | Interactions need checking before a switch or combination |
The UK famotidine product cited here has specific indications and is prescription-only. That does not establish the status of every famotidine presentation in every country.
This guide does not recommend automatically adding famotidine to a PPI for breakthrough symptoms. A clinician or pharmacist should review the existing regimen first.
Kidney function and interactions
Famotidine is mainly eliminated through the kidneys. The product information requires dose review in renal impairment. A standard course may therefore be unsuitable without adjustment by the prescriber.
Changes in stomach acidity can affect absorption of other medicines. Tell the clinician about antifungals, cancer medicines, antacids, supplements and all other products. The full interaction list belongs to the actual medicine's leaflet and prescribing information.
Headache, dizziness, constipation and diarrhoea are possible effects. Rare serious reactions and nervous-system effects are also described. Calling famotidine's long-term profile “lighter” without a defined comparison could obscure those precautions.
What happened to ranitidine?
The EMA ranitidine referral records a 2020 recommendation to suspend ranitidine medicines in the EU because of NDMA impurity concerns.
That is a specific regulatory action concerning ranitidine. It does not establish that all ranitidine products remain unavailable worldwide, or prove that every other H2 blocker has no quality or safety risks.
Preparing for a reflux review
Bring a symptom timeline, the names of current acid medicines and your kidney-health information. Ask whether further investigation is needed and what should trigger review.
Our omeprazole article explains PPI use. Prescrivia is an intermediary; independent clinicians decide suitability. No medicine, access or symptom outcome is guaranteed.
General information only, not medical advice. Follow the leaflet for your actual product and discuss decisions with a qualified clinician. See the current clinical, legal and language review statuses for this edition.
Sources
- Viatris UK famotidine SmPC: H2-receptor mechanism, product indications, renal dose review, interactions and adverse effects.
- NHS PPI information: acid-reduction mechanism, reflux/ulcer indications and individual prescribing considerations.
- EMA ranitidine referral: EU suspension recommendation in 2020 related to NDMA concerns; not a worldwide current-access claim.
Sources checked online on 6 October 2026. Country-specific guidance does not establish availability or prescribing rules throughout Europe.
Related articles
- Why is pantoprazole the PPI preferred with clopidogrel?Prescrivia Editorial · 12 October 2026
- What is esomeprazole (Nexium) used for? Reflux treatment explainedPrescrivia Editorial · 12 October 2026
- What is lansoprazole (Zoton) used for? The dissolvable PPI explainedPrescrivia Editorial · 12 October 2026